NCI-CONNECT: Comprehensive Oncology Network Evaluating Rare CNS Tumors-Histone Mutated Midline Glioma Workshop Proceedings.

Histone mutations occur in approximately 4% of different cancer types. In 2012, mutations were found in the gene encoding histone variant H3.3 (H3F3A gene) in pediatric diffuse intrinsic pontine gliomas and pediatric hemispheric gliomas. Tumors with mutations in the H3F3A gene are generally characterized as histone mutated gliomas (HMGs) or diffuse midline gliomas. HMGs are a rare subtype of glial tumor that is malignant and fast growing, carrying a poor prognosis. In 2017, the Beau Biden Cancer Moonshot Program appropriated $1.7 billion toward cancer care in 10 select areas. The National Cancer Institute (NCI) was granted support to focus specifically on rare central nervous system (CNS) tumors through NCI-CONNECT. Its mission is to address the challenges and unmet needs in CNS cancer research and treatment by connecting patients, providers, researchers, and advocacy organizations to work in partnership. On September 27, 2018, NCI-CONNECT convened a workshop on histone mutated midline glioma, one of the 12 CNS cancers included in its initial portfolio. Three leaders in the field provided an overview of advances in histone mutated midline glioma research. These experts shared observations and experiences related to common scientific and clinical challenges in studying these tumors. Although the clinical focus of this workshop was on adult patients, one important objective was to start a collaborative dialogue between pediatric and adult clinicians and researchers. Meeting participants identified needs for diagnostic and treatment standards, disease biology and biological targets for this cancer, disease-specific trial designs, and developed a list of action items and future direction.

[1]  M. Mehta,et al.  Biological activity of weekly ONC201 in adult recurrent glioblastoma patients. , 2019, Neuro-oncology.

[2]  N. Schultz,et al.  The expanding landscape of ‘oncohistone’ mutations in human cancers , 2019, Nature.

[3]  Giles W. Robinson,et al.  Challenges to curing primary brain tumours , 2019, Nature Reviews Clinical Oncology.

[4]  Jessica M. Rusert,et al.  Dopamine Receptor D5 is a Modulator of Tumor Response to Dopamine Receptor D2 Antagonism , 2018, Clinical Cancer Research.

[5]  Jong-Hee Chang,et al.  Impact of H3.3 K27M Mutation on Prognosis and Survival of Grade IV Spinal Cord Glioma on the Basis of New 2016 World Health Organization Classification of the Central Nervous System. , 2018, Neurosurgery.

[6]  Shawn M. Gillespie,et al.  An active role for neurons in glioma progression: making sense of Scherer’s structures , 2018, Neuro-oncology.

[7]  Huiying Liang,et al.  H3 K27M-mutant diffuse midline gliomas in different anatomical locations. , 2018, Human pathology.

[8]  K. Hoang-Xuan,et al.  FGFR1 actionable mutations, molecular specificities, and outcome of adult midline gliomas , 2018, Neurology.

[9]  W. Stummer,et al.  Diffuse Astrocytoma, IDH-Wildtype: A Dissolving Diagnosis , 2018, Journal of neuropathology and experimental neurology.

[10]  S. Khatua,et al.  Clinical, Radiologic, Pathologic, and Molecular Characteristics of Long-Term Survivors of Diffuse Intrinsic Pontine Glioma (DIPG): A Collaborative Report From the International and European Society for Pediatric Oncology DIPG Registries. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  Tracy T Batchelor,et al.  Developmental and oncogenic programs in H3K27M gliomas dissected by single-cell RNA-seq , 2018, Science.

[12]  Pieter Wesseling,et al.  cIMPACT-NOW update 2: diagnostic clarifications for diffuse midline glioma, H3 K27M-mutant and diffuse astrocytoma/anaplastic astrocytoma, IDH-mutant , 2018, Acta Neuropathologica.

[13]  Christopher W Mount,et al.  Potent antitumor efficacy of anti-GD2 CAR T-cells in H3K27M+ diffuse midline gliomas , 2018, Nature Medicine.

[14]  Dominik Sturm,et al.  Diffuse high-grade gliomas with H3 K27M mutations carry a dismal prognosis independent of tumor location , 2018, Neuro-oncology.

[15]  M. Mann,et al.  Novel and shared neoantigen derived from histone 3 variant H3.3K27M mutation for glioma T cell therapy , 2018, The Journal of experimental medicine.

[16]  Kun Mu,et al.  Integrated Molecular Meta-Analysis of 1,000 Pediatric High-Grade and Diffuse Intrinsic Pontine Glioma , 2017, Cancer cell.

[17]  D. Brachman,et al.  Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study , 2017, The Lancet.

[18]  Damien Y. Duveau,et al.  Targeting neuronal activity-regulated neuroligin-3 dependency in high-grade glioma , 2017, Nature.

[19]  M. Monje,et al.  Wrapped to Adapt: Experience-Dependent Myelination , 2017, Neuron.

[20]  F. Ducray,et al.  Characteristics of H3 K27M-mutant gliomas in adults , 2017, Neuro-oncology.

[21]  M. Berger,et al.  Diffuse non-midline glioma with H3F3A K27M mutation: a prognostic and treatment dilemma , 2017, Acta Neuropathologica Communications.

[22]  P. Wen,et al.  A phase 2 study of the first imipridone ONC201, a selective DRD2 antagonist for oncology, administered every three weeks in recurrent glioblastoma , 2017, Oncotarget.

[23]  Ashley R. Woodfin,et al.  Therapeutic targeting of polycomb and BET bromodomain proteins in diffuse intrinsic pontine gliomas , 2017, Nature Medicine.

[24]  Mariella G. Filbin,et al.  Decoupling genetics, lineages, and microenvironment in IDH-mutant gliomas by single-cell RNA-seq , 2017, Science.

[25]  D. Ziegler,et al.  Pre-Clinical Study of Panobinostat in Xenograft and Genetically Engineered Murine Diffuse Intrinsic Pontine Glioma Models , 2017, PloS one.

[26]  Mariella G. Filbin,et al.  Single-cell RNA-seq supports a developmental hierarchy in human oligodendroglioma , 2016, Nature.

[27]  K. Helin,et al.  Role of the Polycomb Repressive Complex 2 (PRC2) in Transcriptional Regulation and Cancer. , 2016, Cold Spring Harbor perspectives in medicine.

[28]  M. Monje,et al.  Contemporary survival endpoints: an International Diffuse Intrinsic Pontine Glioma Registry study. , 2016, Neuro-oncology.

[29]  G. Reifenberger,et al.  The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary , 2016, Acta Neuropathologica.

[30]  Hai Yan,et al.  The H3.3 K27M mutation results in a poorer prognosis in brainstem gliomas than thalamic gliomas in adults. , 2015, Human pathology.

[31]  Volker Hovestadt,et al.  Adult IDH wild type astrocytomas biologically and clinically resolve into other tumor entities , 2015, Acta Neuropathologica.

[32]  Parag Mallick,et al.  Neuronal Activity Promotes Glioma Growth through Neuroligin-3 Secretion , 2015, Cell.

[33]  Nicholas J. Wang,et al.  Functionally-defined Therapeutic Targets in Diffuse Intrinsic Pontine Glioma , 2015, Nature Medicine.

[34]  D. Johnston,et al.  Alternative lengthening of telomeres is enriched in, and impacts survival of TP53 mutant pediatric malignant brain tumors , 2014, Acta Neuropathologica.

[35]  Shawn M. Gillespie,et al.  Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma , 2014, Science.

[36]  David T. W. Jones,et al.  Reduced H3K27me3 and DNA hypomethylation are major drivers of gene expression in K27M mutant pediatric high-grade gliomas. , 2013, Cancer cell.

[37]  S. Khatua,et al.  Proton beam craniospinal irradiation reduces acute toxicity for adults with medulloblastoma. , 2013, International journal of radiation oncology, biology, physics.

[38]  J. Barnholtz-Sloan,et al.  CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007-2011. , 2012, Neuro-oncology.

[39]  A. Shilatifard,et al.  The super elongation complex (SEC) family in transcriptional control , 2012, Nature Reviews Molecular Cell Biology.

[40]  David T. W. Jones,et al.  K27M mutation in histone H3.3 defines clinically and biologically distinct subgroups of pediatric diffuse intrinsic pontine gliomas , 2012, Acta Neuropathologica.

[41]  David T. W. Jones,et al.  Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma , 2012, Nature.

[42]  Li Ding,et al.  Somatic Histone H3 Alterations in Paediatric Diffuse Intrinsic Pontine Gliomas and Non-Brainstem Glioblastomas , 2012, Nature Genetics.

[43]  T. Zhou,et al.  Temozolomide in the treatment of children with newly diagnosed diffuse intrinsic pontine gliomas: a report from the Children's Oncology Group. , 2011, Neuro-oncology.

[44]  Daniel J Brat,et al.  Temozolomide in the treatment of high-grade gliomas in children: a report from the Children's Oncology Group. , 2011, Neuro-oncology.

[45]  I. Weissman,et al.  Hedgehog-responsive candidate cell of origin for diffuse intrinsic pontine glioma , 2011, Proceedings of the National Academy of Sciences.

[46]  A. Shilatifard,et al.  A COMPASS in the voyage of defining the role of trithorax/MLL‐containing complexes: Linking leukemogensis to covalent modifications of chromatin , 2005, Journal of cellular biochemistry.

[47]  Martin J. van den Bent,et al.  Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. , 2005, The New England journal of medicine.

[48]  R. Mirimanoff,et al.  MGMT gene silencing and benefit from temozolomide in glioblastoma. , 2005, The New England journal of medicine.

[49]  M. Osaka,et al.  MSF (MLL septin-like fusion), a fusion partner gene of MLL, in a therapy-related acute myeloid leukemia with a t(11;17)(q23;q25). , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[50]  M. Monje,et al.  Supplemental Information Transcriptional Dependencies in Diffuse Intrinsic Pontine Glioma , 2017 .

[51]  Jill S Barnholtz-Sloan,et al.  CBTRUS Statistical Report: Primary brain and other central nervous system tumors diagnosed in the United States in 2010–2014 , 2017, Neuro-oncology.

[52]  S. Puget,et al.  Is biopsy safe in children with newly diagnosed diffuse intrinsic pontine glioma , 2012 .